HighTide Therapeutics (HKSE:02511) Cash, Cash Equivalents, Marketable Securities : HK$523.72 Mil (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is HighTide Therapeutics Cash, Cash Equivalents, Marketable Securities?

HighTide Therapeutics's quarterly cash, cash equivalents, marketable securities declined from Dec. 2023 (HK$804.69 Mil) to Jun. 2024 (HK$606.57 Mil) but then stayed the same from Jun. 2024 (HK$606.57 Mil) to Dec. 2024 (HK$523.72 Mil).

HighTide Therapeutics's annual cash, cash equivalents, marketable securities declined from Dec. 2022 (HK$938.26 Mil) to Dec. 2023 (HK$804.69 Mil) and declined from Dec. 2023 (HK$804.69 Mil) to Dec. 2024 (HK$523.72 Mil).

HighTide Therapeutics Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for HighTide Therapeutics's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HighTide Therapeutics Cash, Cash Equivalents, Marketable Securities Chart

HighTide Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Cash, Cash Equivalents, Marketable Securities

937.07

938.26

804.69

523.72

HighTide Therapeutics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial			938.26	801.65	804.69	606.57	523.72

HighTide Therapeutics Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

HighTide Therapeutics (HKSE:02511) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

HighTide Therapeutics Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of HighTide Therapeutics's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

HighTide Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HighTide Therapeutics Inc (HKSE:02511) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

Building D, Guangdong, Floor 9 to 10, Fubao Community, Futian District, Shenzhen-Hong Kong Science and, Technology Innovation Cooperation Zone, Shenzhen, CHN, 518112

Website

https://www.hightidetx.com

HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The company has developed a product pipeline of five product candidates in-house, covering nine indications in metabolic and digestive diseases among which, five are at clinical-stage. The Core Product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases.

Executives

Ma Lixiong	2101 Beneficial owner
Liu Liping	2101 Beneficial owner
Li Tan	2202 Interest of your spouse
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.	2501 Other
Li Li	2201 Interest of corporation controlled by you
The Core Trust Company Limited
Shan Miao	2201 Interest of corporation controlled by you
Medi Prosperity Capital Inc.	2201 Interest of corporation controlled by you
Hepalink Healthcare Partners I L.p	2201 Interest of corporation controlled by you
Hepalink Biotechnology Ii Limited	2101 Beneficial owner
Hepalink (hong Kong) Limited	2201 Interest of corporation controlled by you
Wisdom Spring Group Limited
Tct (bvi) Limited
Baiyi Capital Limited	2101 Beneficial owner
Lai Hoi Man	2201 Interest of corporation controlled by you

HighTide Therapeutics Headlines

No Headlines